Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

celgene australia pty ltd - azacitidine -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine accord is indicated for the treatment of patients with,? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ,? chronic myelomonocytic leukemia (cmmol (10-29 percent marrow blasts without myeloproliferative disorder)), ,? acute myeloid leukemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who), ,in whom allogenic stem cell transplantation is not indicated.

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

celgene limited, a bristol myers squibb company - azacitidine 100mg;   - powder for injection - 100 mg - active: azacitidine 100mg   excipient: mannitol - indicated for the treatment of patients with: - intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss) in whom allogenic stem cell transplantation is not indicated.

Малезија - Енглески - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

celgene sdn. bhd. - azacitidine -

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - azacitidine 100mg (105 mg per vial including 5% manufacturing overage) - powder for injection - 100 mg - active: azacitidine 100mg (105 mg per vial including 5% manufacturing overage) excipient: mannitol - indicated for the treatment of patients with: - intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss). - chronic myelomonocytic leukaemia (cmmol [10%-29% marrow blasts without myeloproliferative disorder]). - acute myeloid leukaemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification, in whom allogenic stem cell transplantation is not indicated.

Јужноафричка Република - Енглески - South African Health Products Regulatory Authority (SAHPRA)

key oncologics (pty) ltd - injection - see ingredients - each 1,0 ml suspension contains azacitidine 25,0 mg

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine is indicated for the treatment of patients with: ? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ? chronic myelomonocytic leukemia [cmmol (10%-29% marrow blasts without myeloproliferative disorder)], ? acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who), in whom allogenic stem cell transplantation is not indicated.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine is indicated for the treatment of patients with: ? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ? chronic myelomonocytic leukemia [cmmol (10%-29% marrow blasts without myeloproliferative disorder)], ? acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who), in whom allogenic stem cell transplantation is not indicated.